Literature DB >> 31882306

To be or not to be on CFTR modulators during pregnancy: Risks to be considered.

Sona Vekaria1, Natalia Popowicz2, Scott W White3, Siobhain Mulrennan4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31882306     DOI： 10.1016/j.jcf.2019.12.004

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN： 1569-1993            Impact factor:   5.482


× No keyword cloud information.
  5 in total

Review 1.  Challenges in the use of highly effective modulator treatment for cystic fibrosis.

Authors:  Kathleen J Ramos; Joseph M Pilewski; Jennifer L Taylor-Cousar
Journal:  J Cyst Fibros       Date:  2021-01-30       Impact factor: 5.482

Review 2.  Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review.

Authors:  Renée V E Dagenais; Victoria C H Su; Bradley S Quon
Journal:  J Clin Med       Date:  2020-12-23       Impact factor: 4.241

Review 3.  Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now?

Authors:  Eva Choong; Alain Sauty; Angela Koutsokera; Sylvain Blanchon; Pascal André; Laurent Decosterd
Journal:  Pharmaceutics       Date:  2022-08-11       Impact factor: 6.525

Review 4.  Fertility, Pregnancy and Lactation Considerations for Women with CF in the CFTR Modulator Era.

Authors:  Raksha Jain; Jennifer L Taylor-Cousar
Journal:  J Pers Med       Date:  2021-05-15

Review 5.  The Changing Epidemiology of Cystic Fibrosis: Incidence, Survival and Impact of the CFTR Gene Discovery.

Authors:  Virginie Scotet; Carine L'Hostis; Claude Férec
Journal:  Genes (Basel)       Date:  2020-05-26       Impact factor: 4.096
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.